Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.84 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.46 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.46 |
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1919 | 0.92 | — | — | |
| SCHEMBL8995751 | 0.89 | HSD17B10 (0.94) | HSD17B10CYP1A2ALDH1A1KDM4EPOLB | |
| SCHEMBL28981622 | 0.89 | HSD17B10 (0.94) | HSD17B10CYP1A2ALDH1A1KDM4EPOLB | |
| SCHEMBL31544783 | 0.89 | HSD17B10 (0.94) | HSD17B10CYP1A2ALDH1A1KDM4ETYR | |
| Hydrochloric Acid SCHEMBL5255687 | 0.89 | HSD17B10 (0.94) | HSD17B10CYP1A2ALDH1A1KDM4EPOLB | |
| SCHEMBL4391231 | 0.89 | HSD17B10 (0.67) | HSD17B10HDAC2CYP1A2ALDH1A1KDM4E | |
| SCHEMBL10693495 | 0.87 | HSD17B10 (0.64) | HSD17B10ALDH1A1KDM4EPOLBSMN1; SMN2 | |
| Ethane SCHEMBL2154693 | 0.86 | HSD17B10 (0.89) | HSD17B10CYP1A2ALDH1A1KDM4ETYR | |
| SCHEMBL25288128 | 0.86 | CYP2A6 (0.58) | HSD17B10ALDH1A1KDM4EDRD1TYR | |
| SCHEMBL976904 | 0.86 | CYP2A6 (0.58) | HSD17B10ALDH1A1KDM4EDRD1TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4509178-A2 | HIGH PURITY ORITAVANCIN AND METHOD OF PRODUCING SAME | Melinta Therapeutics, LLC (US) | 2025-02-19 | — | — | EP | claimed |
| EP-3169345-B1 | HIGH PURITY ORITAVANCIN AND METHOD OF PRODUCING SAME | MELINTA THERAPEUTICS LLC (US) | 2025-01-29 | — | — | EP | claimed |
| CN-117658785-A | Preparation method of olanzapine side chain and preparation method of olanzapine | 广东新达瑞生物科技有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-107434823-B | Purification method of oritavancin intermediate A82846B | 江苏恒瑞医药股份有限公司 | 2021-11-16 | — | — | CN | claimed |
| CN-109053864-B | Method for preparing oritavancin | 丽珠集团新北江制药股份有限公司 | 2021-08-24 | — | — | CN | claimed |
| CN-109053865-B | Method for preparing oritavancin by carboxyl protection | 丽珠集团新北江制药股份有限公司 | 2021-04-13 | — | — | CN | claimed |
| US-10864249-B2 | High purity oritavancin and method of producing same | MELINTA THERAPEUTICS, INC. (US) | 2020-12-15 | — | — | US | claimed |
| CN-106467570-B | Reductive alkylation method of glycopeptide antibiotics | 正大天晴药业集团股份有限公司 | 2020-04-07 | — | — | CN | claimed |
| US-20190290723-A1 | HIGH PURITY ORITAVANCIN AND METHOD OF PRODUCING SAME | MELINTA THERAPEUTICS INC. (US) | 2019-09-26 | — | — | US | claimed |
| US-20170157206-A1 | HIGH PURITY ORITAVANCIN AND METHOD OF PRODUCING SAME | THE MEDICINES COMPANY (US) | 2017-06-08 | — | — | US | claimed |
| EP-1075480-A1 | PURIFICATION OF CARBOXALDEHYDE | ELI LILLY AND COMPANY (US) | 2001-02-14 | — | — | EP | claimed |
| EP-1031576-A2 | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 2000-08-30 | — | — | EP | claimed |
| US-5998581-A | PROVIDING SOURCE OF COPPER WHICH RESULTS IN THE INITIAL PRODUCTION OF A COPPER COMPLEX OF THE GLYCOPEPTIDE ANTIBIOTIC; REDUCTIVE ALKYLATION OF THIS COMPLEX FAVORS REGIOSELECTIVE ALKYLATION AND INCREASED YIELDS | ELI LILLY AND COMPANY (US) | 1999-12-07 | — | — | US | claimed |
| WO-1999057123-A1 | PURIFICATION OF CARBOXALDEHYDE | ELI LILLY AND COMPANY (US) | 1999-11-11 | — | — | WO | claimed |
| US-5952466-A | INCREASED YIELD, REGIOSELECTIVE PROCESS BY REACTING SOLUBLE COPPER COMPLEX OF ANTIBIOTIC HAVING SACCHARIDE WITH AMINE AT N4 WITH KETONE OR ALDEHYDE IN PRESENCE OF SODIUM CYANOBOROHYDRIDE OR PYRIDINE*BORANE COMPLEX | ELI LILLY AND COMPANY (US) | 1999-09-14 | — | — | US | claimed |
| US-5939382-A | PYRIDINE-BORANE AS A REDUCING AGENT | ELI LILLY AND COMPANY (US) | 1999-08-17 | — | — | US | claimed |
| EP-0845478-A1 | Reductive alkylation of glycopeptide antibiotics | ELI LILLY AND COMPANY (US) | 1998-06-03 | — | — | EP | claimed |
| EP-0845477-A1 | Reducing agent for reductive alkylation of glycopeptide antibiotics | ELI LILLY AND COMPANY (US) | 1998-06-03 | — | — | EP | claimed |
| EP-0037697-A1 | Dioxolane derivatives for use as chemical intermediates | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-10-14 | — | — | EP | claimed |
| EP-0037698-A1 | Benzaldehyde derivatives for use as a chemical intermediate | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-10-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10864249-B2 | High purity oritavancin and method of producing same | OSGEP, SRI, OSTC | HSD17B10 2567/4885HDAC2 2165/4885CYP1A2 1961/4885 |
| US-20170157206-A1 | HIGH PURITY ORITAVANCIN AND METHOD OF PRODUCING SAME | OSGEP, SRI, OSTC | HSD17B10 2567/4885HDAC2 2165/4885CYP1A2 1961/4885 |
| US-20190290723-A1 | HIGH PURITY ORITAVANCIN AND METHOD OF PRODUCING SAME | OSGEP, SRI, OSTC | HSD17B10 2567/4885HDAC2 2165/4885CYP1A2 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.